title: Clofarabine.
abstract: Clofarabine (Clolar; Genzyme), a purine nucleoside antimetabolite, was granted accelerated approval by the US FDA for the treatment of paediatric patients with relapsed or refractory acute lymphoblastic leukaemia in December 2004. It is the first new drug for paediatric leukaemia to be approved in more than a decade, and the only one to receive approval for paediatric use before adult use.
authors.affiliation: Leukemia/Lymphoma Division, St Jude Children's Research Hospital, Memphis, Tennessee 38105-2794, USA. ching-hon.pui@stjude.org
authors.forename: Ching-Hon
authors.initials: CH
authors.lastname: Pui
authors.forename: Sima
authors.initials: S
authors.lastname: Jeha
mesh_terms: D000227:Adenine Nucleotides; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001087:Arabinonucleosides / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D000077866:Clofarabine; D004247:DNA / Q000096:biosynthesis; D006801:Humans; D019384:Nucleic Acid Synthesis Inhibitors; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism; D012264:Ribonucleotide Reductases / Q000037:antagonists & inhibitors; D016896:Treatment Outcome
chemical_list: D000227:Adenine Nucleotides; D000970:Antineoplastic Agents; D001087:Arabinonucleosides; D019384:Nucleic Acid Synthesis Inhibitors; D000077866:Clofarabine; D004247:DNA; D012264:Ribonucleotide Reductases